IMP-1088 is primarily recognized for its potential in cancer research and therapy. It functions as a potent inhibitor of N-myristoyltransferases (NMTs), enzymes that play a critical role in the modification of proteins necessary for cancer cell survival and proliferation. By inhibiting NMTs, IMP-1088 disrupts the proper functioning of these proteins, leading to the suppression of cancer cell growth. This makes it a promising candidate for the development of targeted cancer treatments, particularly in cases where traditional therapies have proven ineffective. Additionally, its mechanism of action is being studied to understand its applicability in combating drug-resistant cancers, offering a new avenue for therapeutic intervention. Research is ongoing to explore its efficacy and safety in preclinical and clinical settings.